Advaxis, Inc. - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
ADXS Over the counter 8731 https://www.advaxis.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Advaxis, Inc.

Advaxis to Present Updated Clinical and Immunogenicity Data from Ongoing Phase 1/2 Trial of ADXS-503 in Metastatic Non-Small-Cell Lung Cancer (NSCLC) and Study Design of ADXS-504 Trial in Early Prostate Cancer at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting - May 26th, 2022 9:00 pm
Advaxis to Present at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting - Apr 27th, 2022 2:00 pm
Advaxis Announces Publication of ADXS-PSA Data in The Oncologist - Apr 8th, 2022 12:00 pm
ADXS Investor Alert – Monteverde & Associates PC and Kahn Swick & Foti, LLC Obtain Material Disclosures Regarding the Upcoming Shareholder Vote for Advaxis, Inc. - ADXS - Mar 28th, 2022 4:59 pm
Advaxis Reports First Quarter Ended January 31, 2022 Financial Results and Provides a Business Update - Mar 17th, 2022 1:00 pm
Advaxis Reports Fiscal Year 2021 Financial Results and Provides a Business Update - Feb 14th, 2022 9:35 pm
Advaxis Prices Offering of $5,000,000 of Convertible Redeemable Preferred Stock Through a Private Placement - Jan 28th, 2022 1:00 pm
Advaxis Presents Updated Clinical Data from Ongoing Phase 1/2 Trial of ADXS-503 in NSCLC and Upcoming Milestones - Jan 11th, 2022 1:00 pm
OTC Markets Group Welcomes Advaxis, Inc. to OTCQX - Dec 23rd, 2021 12:00 pm
Advaxis Announces Acceptance for Trading on the OTCQX - Dec 22nd, 2021 9:05 pm
Advaxis to Continue to Explore Additional Options to Maximize Stockholder Value - Dec 17th, 2021 1:00 pm
Advaxis Issues Letter to Stockholders Regarding Recent Special Meeting Results - Dec 9th, 2021 1:00 pm
Advaxis Issues Letter and Second Video Message to Stockholders Regarding Upcoming Special Meeting - Nov 24th, 2021 1:00 pm
Nasdaq Grants Advaxis, Inc. an Extension to December 20, 2021, to Complete Merger Transaction with Biosight, Ltd. and Satisfy Initial Listing Requirements - Nov 22nd, 2021 1:00 pm
Advaxis, Inc. Issues Letter to Stockholders - Nov 19th, 2021 1:00 pm
Leading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending Advaxis Stockholders Vote “FOR” Proposed Merger with Biosight - Nov 18th, 2021 1:00 pm
Biosight Encourages Advaxis Stockholders to Vote “FOR” Proposed Merger - Nov 11th, 2021 1:00 pm
Advaxis Issues Letter and Video Message to Stockholders Regarding Upcoming Special Meeting - Nov 4th, 2021 12:00 pm
Leading Independent Proxy Advisory Firm ISS Recommends Advaxis Stockholders Vote “FOR” the Merger with Biosight - Nov 3rd, 2021 12:00 pm
6 of the Hottest Stocks to Pick Up for Less Than $1 - Nov 1st, 2021 4:18 pm